JDR JDR Most Cited Articles
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Konopka, K.
Right arrow Articles by Duzgunes, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Konopka, K.
Right arrow Articles by Duzgunes, N.

Journal of Dental Research, Vol 78, 1773-1776, Copyright © 1999 by International & American Associations for Dental Research Online Journals


ARTICLES

Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity

K. Konopka, N. Shine, E. Pretzer and N. Duzgunes
Department of Microbiology, School of Dentistry, University of the Pacific, San Francisco, California 94115-2399, USA.

Secretory leukocyte protease inhibitor (SLPI) has been proposed as a potential inhibitor of HIV-1 infection in human saliva. Although the ability of recombinant (r) SLPI to inhibit HIV-1 infection of macrophages and primary T-cells has been demonstrated by two independent laboratories, evidence to the contrary has also been reported. This study re-examines the anti-HIV effect of rSLPI and investigates the effects of repeated freeze-thawing and oxidation on the anti-HIV activity of rSLPI. rSLPI inhibited HIV-1BaL infection of human macrophages in a highly variable manner. HPLC and electrospray ionization mass spectrometry (ESI) analyses indicated that variability in our inhibition data could not be attributed to the degradation or oxidation of rSLPI. These results suggest that the variable anti-HIV effect of rSLPI may be due to differential expression of the cell-surface molecule(s) to which SLPI binds rather than to changes in the rSLPI molecule.


This article has been cited by other articles:


Home page
CVIHome page
S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe
Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids
Clin. Vaccine Immunol., October 1, 2006; 13(10): 1111 - 1118.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
N. K. Jana, L. R. Gray, and D. C. Shugars
Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity
J. Virol., May 15, 2005; 79(10): 6432 - 6440.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Doumas, A. Kolokotronis, and P. Stefanopoulos
Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor
Infect. Immun., March 1, 2005; 73(3): 1271 - 1274.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Geiben-Lynn, N. Brown, B. D. Walker, and A. D. Luster
Purification of a Modified Form of Bovine Antithrombin III as an HIV-1 CD8+ T-cell Antiviral Factor
J. Biol. Chem., October 25, 2002; 277(44): 42352 - 42357.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
IADR Journals Advances in Dental Research ®
Journal of Dental Research ® Critical Reviews (1990-2004)
Copyright © 1999 Institutional Access Guidelines